Adanate Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $30M

  • Investors
  • 5

Adanate General Information

Description

Developer of antibody therapeutics designed to enhance innate and adaptive immunity to control cancer. The company's technology is based on the immune-regulating capacity of a family of receptors, which are key in orchestrating a coordinated effort to dampen innate and adaptive immunity across multiple cell types, including macrophages, dendritic cells, natural killer cells, and T-cells, enabling doctors to help with a novel treatment strategy that allows for better control of cancer.

Contact Information

Website
www.adanate.com
Formerly Known As
T-Rx Pharmaceuticals
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1010 Atlantic Avenue
  • Suite 102
  • Alameda, CA 94501
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1010 Atlantic Avenue
  • Suite 102
  • Alameda, CA 94501
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adanate Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 17-Nov-2021 $30M Completed Clinical Trials - General
1. Seed Round 19-Jun-2018 Completed Startup
To view Adanate’s complete valuation and funding history, request access »

Adanate Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view Adanate’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Adanate Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of antibody therapeutics designed to enhance innate and adaptive immunity to control cancer. The company's tec
Drug Discovery
Alameda, CA
3 As of 2025

South San Francisco, CA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Adanate Competitors (2)

One of Adanate’s 2 competitors is Nkarta Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nkarta Therapeutics Formerly VC-backed South San Francisco, CA
Pyxis Oncology Formerly VC-backed Boston, MA
You’re viewing 2 of 2 competitors. Get the full list »

Adanate Patents

Adanate Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025128648-A1 Multispecific antibodies Inactive 12-Dec-2023
AU-2024261307-A1 Anti-p95her2 antibodies and methods for their use Pending 24-Apr-2023
AU-2024261307-A9 Anti-p95her2 antibodies and methods for their use Pending 24-Apr-2023
EP-4705344-A2 Anti-p95her2 antibodies and methods for their use Pending 24-Apr-2023
US-20240360244-A1 Anti-p95her2 antibodies and methods for their use Pending 24-Apr-2023 C07K16/32
To view Adanate’s complete patent history, request access »

Adanate Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Adanate Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Avalon Bioventures Venture Capital Minority
Corner Capital Management Venture Capital Minority
Westlake Village BioPartners Venture Capital Minority
Avalon Ventures Venture Capital Minority
Bregua Corporation Venture Capital Minority
To view Adanate’s complete investors history, request access »

Adanate FAQs

  • When was Adanate founded?

    Adanate was founded in 2017.

  • Where is Adanate headquartered?

    Adanate is headquartered in Alameda, CA.

  • What is the size of Adanate?

    Adanate has 3 total employees.

  • What industry is Adanate in?

    Adanate’s primary industry is Drug Discovery.

  • Is Adanate a private or public company?

    Adanate is a Private company.

  • What is the current valuation of Adanate?

    The current valuation of Adanate is .

  • What is Adanate’s current revenue?

    The current revenue for Adanate is .

  • How much funding has Adanate raised over time?

    Adanate has raised $32M.

  • Who are Adanate’s investors?

    Avalon Bioventures, Corner Capital Management, Westlake Village BioPartners, Avalon Ventures, and Bregua Corporation have invested in Adanate.

  • Who are Adanate’s competitors?

    Nkarta Therapeutics and Pyxis Oncology are competitors of Adanate.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process